Se agrega que el modo de accin detrs del posible efecto renal observado con los AR-GLP1 an no est completamente entendido
Sociodemographic (sex, age), treatment-related (GLP-1 RAs prescribed, GLP-1 RA dosage, concomitant treatments, additional diabetes treatment, administration route of previous treatment), and clinical variables (weight, BMI, comorbidities, time between HbA1c tests, HbA1c difference before starting treatment with weekly injectable dulaglutide or daily oral semaglutide and last available value, time from diagnosis to treatment onset, time from treatment onset to patient inclusion) were explored as drivers of participant-reported compliance
Nausea affects 15-44% of patients, particularly during initial treatment or dose increases
Stay proactive about hydration, diet, and exercise habits, and consult a healthcare provider if necessary